Premium
Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome
Author(s) -
Laine Marc,
Panagides Vassili,
Frère Corinne,
Cuisset Thomas,
Gouarne Caroline,
Jouve Bernard,
Thuny Franck,
Paganelli Franck,
Alessi MarieChristine,
Mancini Julien,
Bonello Laurent
Publication year - 2019
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.14592
Subject(s) - medicine , ticagrelor , mace , percutaneous coronary intervention , clopidogrel , acute coronary syndrome , cardiology , conventional pci , myocardial infarction , loading dose , stent
Background Ticagrelor induces more potent platelet reactivity ( PR ) inhibition with reduced interindividual variability compared to clopidogrel. Although on‐clopidogrel PR was shown to correlate with ischemia and bleeding events, no study has investigated the relationship between on‐ticagrelor PR and outcome. Objectives We aimed to evaluate the relationship between on‐ticagrelor PR , assessed by the vasodilator‐stimulated phosphoprotein index ( VASP ), and thrombotic and bleeding events in patients with acute coronary syndrome ( ACS ) treated by percutaneous coronary intervention ( PCI ). Methods We performed a prospective, multicenter observational study on patients treated with PCI for ACS . The VASP index was used to assess PR after ticagrelor loading dose ( LD ). The primary endpoint was the link between major adverse cardiovascular events ( MACE ) and PR . Results Among the 530 patients with ACS included , 183 (34.5%) were admitted for ST elevation myocardial infarction. We observed high potency and limited interindividual variability after the ticagrelor LD ( VASP 19.1% ± 16.6%). At 1 month, 21 (3.8%) MACE and 29 (5.5%) bleedings ≥ 2 according to the Bleedings Academic Research Consortium (BARC) scale were recorded. Neither MACE nor bleeding was associated with PR ( P = .34 and P = .78, respectively). However, there was a strong association between PR and the occurrence of definite acute stent thrombosis ( P = .03). Platelet reactivity was the only factor associated with acute definite stent thrombosis. Conclusion In patients receiving a ticagrelor LD while undergoing PCI for ACS , PR using the VASP did not predict MACE or bleeding, but it was significantly associated with the occurrence of definite acute stent thrombosis.